http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 17 Jul 2026 09:11:22 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Xencor+to+present+XmAb819+renal+cancer+data+at+ESMO+2026/26782456.html <p>Xencor, Inc. (NASDAQ: XNCR) announced that Phase 1 study results of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in advanced clear cell renal cell carcinoma (ccRCC) will be presented as a proffered paper oral presentation at the European Society of Medical Oncology (ESMO) Congress 2026, scheduled for October 23-27 in Madrid, Spain.</p> <p>The presentation, titled "Phase 1 results of XmAb819, a novel ENPP3 x CD3 bispecific, in advanced clear cell renal cell carcinoma (ccRCC)," will be delivered by Sumanta Pal, M.D., FASCO, Professor and Vice Chair of Academic Affairs at City of Hope Comprehensive Cancer Center. The related abstract http://www.streetinsider.com/FDA/Xencor+to+present+XmAb819+renal+cancer+data+at+ESMO+2026/26782456.html Fri, 17 Jul 2026 09:11:22 -0400 A.11505694 O.00017340 O.71890331 XNCR http://www.streetinsider.com/FDA/Xencor+to+present+XmAb819+renal+cancer+data+at+ESMO+2026/26782456.html <p>Xencor, Inc. (NASDAQ: XNCR) announced that Phase 1 study results of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in advanced clear cell renal cell carcinoma (ccRCC) will be presented as a proffered paper oral presentation at the European Society of Medical Oncology (ESMO) Congress 2026, scheduled for October 23-27 in Madrid, Spain.</p> <p>The presentation, titled "Phase 1 results of XmAb819, a novel ENPP3 x CD3 bispecific, in advanced clear cell renal cell carcinoma (ccRCC)," will be delivered by Sumanta Pal, M.D., FASCO, Professor and Vice Chair of Academic Affairs at City of Hope Comprehensive Cancer Center. The related abstract http://www.streetinsider.com/FDA/Xencor+to+present+XmAb819+renal+cancer+data+at+ESMO+2026/26782456.html Fri, 17 Jul 2026 09:11:22 -0400 A.11505694 O.00017340 O.71890331 XNCR http://www.streetinsider.com/FDA/Xencor+to+present+XmAb819+renal+cancer+data+at+ESMO+2026/26782456.html <p>Xencor, Inc. (NASDAQ: XNCR) announced that Phase 1 study results of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in advanced clear cell renal cell carcinoma (ccRCC) will be presented as a proffered paper oral presentation at the European Society of Medical Oncology (ESMO) Congress 2026, scheduled for October 23-27 in Madrid, Spain.</p> <p>The presentation, titled "Phase 1 results of XmAb819, a novel ENPP3 x CD3 bispecific, in advanced clear cell renal cell carcinoma (ccRCC)," will be delivered by Sumanta Pal, M.D., FASCO, Professor and Vice Chair of Academic Affairs at City of Hope Comprehensive Cancer Center. The related abstract http://www.streetinsider.com/FDA/Xencor+to+present+XmAb819+renal+cancer+data+at+ESMO+2026/26782456.html Fri, 17 Jul 2026 09:11:22 -0400 A.11505694 O.00017340 O.71890331 XNCR http://www.streetinsider.com/FDA/Xencor+to+present+XmAb819+renal+cancer+data+at+ESMO+2026/26782456.html <p>Xencor, Inc. (NASDAQ: XNCR) announced that Phase 1 study results of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in advanced clear cell renal cell carcinoma (ccRCC) will be presented as a proffered paper oral presentation at the European Society of Medical Oncology (ESMO) Congress 2026, scheduled for October 23-27 in Madrid, Spain.</p> <p>The presentation, titled "Phase 1 results of XmAb819, a novel ENPP3 x CD3 bispecific, in advanced clear cell renal cell carcinoma (ccRCC)," will be delivered by Sumanta Pal, M.D., FASCO, Professor and Vice Chair of Academic Affairs at City of Hope Comprehensive Cancer Center. The related abstract http://www.streetinsider.com/FDA/Xencor+to+present+XmAb819+renal+cancer+data+at+ESMO+2026/26782456.html Fri, 17 Jul 2026 09:11:22 -0400 A.11505694 O.00017340 O.71890331 XNCR http://www.streetinsider.com/Press+Releases/Xencor+Announces+Proffered+Paper+Oral+Presentation+at+ESMO+2026+for+Phase+1+Clinical+Study+of+XmAb819+in+Advanced+Clear+Cell+Renal+Cell+Carcinoma/26782454.html <p class="bwalignc">-- ESMO presentation to highlight expansion-cohort results for IV doses evaluated for recommended Phase 3 dose --</p><p class="bwalignc">-- Pivotal study of XmAb819 monotherapy in advanced ccRCC, planned to begin in 2027 --</p> <p> PASADENA, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl">Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that results from a Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in advanced clear cell renal cell carcinoma (ccRCC) were accepted for a proffered paper oral presentation at the European Society of Medical Oncology (ESMO) http://www.streetinsider.com/Press+Releases/Xencor+Announces+Proffered+Paper+Oral+Presentation+at+ESMO+2026+for+Phase+1+Clinical+Study+of+XmAb819+in+Advanced+Clear+Cell+Renal+Cell+Carcinoma/26782454.html Fri, 17 Jul 2026 09:11:00 -0400 A.11505694 O.00017340 O.71890331 XNCR http://www.streetinsider.com/Press+Releases/Xencor+Announces+Proffered+Paper+Oral+Presentation+at+ESMO+2026+for+Phase+1+Clinical+Study+of+XmAb819+in+Advanced+Clear+Cell+Renal+Cell+Carcinoma/26782454.html <p class="bwalignc">-- ESMO presentation to highlight expansion-cohort results for IV doses evaluated for recommended Phase 3 dose --</p><p class="bwalignc">-- Pivotal study of XmAb819 monotherapy in advanced ccRCC, planned to begin in 2027 --</p> <p> PASADENA, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl">Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that results from a Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in advanced clear cell renal cell carcinoma (ccRCC) were accepted for a proffered paper oral presentation at the European Society of Medical Oncology (ESMO) http://www.streetinsider.com/Press+Releases/Xencor+Announces+Proffered+Paper+Oral+Presentation+at+ESMO+2026+for+Phase+1+Clinical+Study+of+XmAb819+in+Advanced+Clear+Cell+Renal+Cell+Carcinoma/26782454.html Fri, 17 Jul 2026 09:11:00 -0400 A.11505694 O.00017340 O.71890331 XNCR http://www.streetinsider.com/Press+Releases/Xencor+Announces+Proffered+Paper+Oral+Presentation+at+ESMO+2026+for+Phase+1+Clinical+Study+of+XmAb819+in+Advanced+Clear+Cell+Renal+Cell+Carcinoma/26782454.html <p class="bwalignc">-- ESMO presentation to highlight expansion-cohort results for IV doses evaluated for recommended Phase 3 dose --</p><p class="bwalignc">-- Pivotal study of XmAb819 monotherapy in advanced ccRCC, planned to begin in 2027 --</p> <p> PASADENA, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl">Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that results from a Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in advanced clear cell renal cell carcinoma (ccRCC) were accepted for a proffered paper oral presentation at the European Society of Medical Oncology (ESMO) http://www.streetinsider.com/Press+Releases/Xencor+Announces+Proffered+Paper+Oral+Presentation+at+ESMO+2026+for+Phase+1+Clinical+Study+of+XmAb819+in+Advanced+Clear+Cell+Renal+Cell+Carcinoma/26782454.html Fri, 17 Jul 2026 09:11:00 -0400 A.11505694 O.00017340 O.71890331 XNCR http://www.streetinsider.com/Press+Releases/Xencor+Announces+Proffered+Paper+Oral+Presentation+at+ESMO+2026+for+Phase+1+Clinical+Study+of+XmAb819+in+Advanced+Clear+Cell+Renal+Cell+Carcinoma/26782454.html <p class="bwalignc">-- ESMO presentation to highlight expansion-cohort results for IV doses evaluated for recommended Phase 3 dose --</p><p class="bwalignc">-- Pivotal study of XmAb819 monotherapy in advanced ccRCC, planned to begin in 2027 --</p> <p> PASADENA, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl">Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that results from a Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in advanced clear cell renal cell carcinoma (ccRCC) were accepted for a proffered paper oral presentation at the European Society of Medical Oncology (ESMO) http://www.streetinsider.com/Press+Releases/Xencor+Announces+Proffered+Paper+Oral+Presentation+at+ESMO+2026+for+Phase+1+Clinical+Study+of+XmAb819+in+Advanced+Clear+Cell+Renal+Cell+Carcinoma/26782454.html Fri, 17 Jul 2026 09:11:00 -0400 A.11505694 O.00017340 O.71890331 XNCR http://www.streetinsider.com/Business+Wire/Xencor+Announces+Proffered+Paper+Oral+Presentation+at+ESMO+2026+for+Phase+1+Clinical+Study+of+XmAb819+in+Advanced+Clear+Cell+Renal+Cell+Carcinoma/26782454.html <p class="bwalignc">-- ESMO presentation to highlight expansion-cohort results for IV doses evaluated for recommended Phase 3 dose --</p><p class="bwalignc">-- Pivotal study of XmAb819 monotherapy in advanced ccRCC, planned to begin in 2027 --</p> <p> PASADENA, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl">Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that results from a Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in advanced clear cell renal cell carcinoma (ccRCC) were accepted for a proffered paper oral presentation at the European Society of Medical Oncology (ESMO) http://www.streetinsider.com/Business+Wire/Xencor+Announces+Proffered+Paper+Oral+Presentation+at+ESMO+2026+for+Phase+1+Clinical+Study+of+XmAb819+in+Advanced+Clear+Cell+Renal+Cell+Carcinoma/26782454.html Fri, 17 Jul 2026 09:11:00 -0400 A.11505694 O.00017340 O.71890331 XNCR http://www.streetinsider.com/Business+Wire/Xencor+Announces+Proffered+Paper+Oral+Presentation+at+ESMO+2026+for+Phase+1+Clinical+Study+of+XmAb819+in+Advanced+Clear+Cell+Renal+Cell+Carcinoma/26782454.html <p class="bwalignc">-- ESMO presentation to highlight expansion-cohort results for IV doses evaluated for recommended Phase 3 dose --</p><p class="bwalignc">-- Pivotal study of XmAb819 monotherapy in advanced ccRCC, planned to begin in 2027 --</p> <p> PASADENA, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl">Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that results from a Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in advanced clear cell renal cell carcinoma (ccRCC) were accepted for a proffered paper oral presentation at the European Society of Medical Oncology (ESMO) http://www.streetinsider.com/Business+Wire/Xencor+Announces+Proffered+Paper+Oral+Presentation+at+ESMO+2026+for+Phase+1+Clinical+Study+of+XmAb819+in+Advanced+Clear+Cell+Renal+Cell+Carcinoma/26782454.html Fri, 17 Jul 2026 09:11:00 -0400 A.11505694 O.00017340 O.71890331 XNCR http://www.streetinsider.com/Business+Wire/Xencor+Announces+Proffered+Paper+Oral+Presentation+at+ESMO+2026+for+Phase+1+Clinical+Study+of+XmAb819+in+Advanced+Clear+Cell+Renal+Cell+Carcinoma/26782454.html <p class="bwalignc">-- ESMO presentation to highlight expansion-cohort results for IV doses evaluated for recommended Phase 3 dose --</p><p class="bwalignc">-- Pivotal study of XmAb819 monotherapy in advanced ccRCC, planned to begin in 2027 --</p> <p> PASADENA, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl">Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that results from a Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in advanced clear cell renal cell carcinoma (ccRCC) were accepted for a proffered paper oral presentation at the European Society of Medical Oncology (ESMO) http://www.streetinsider.com/Business+Wire/Xencor+Announces+Proffered+Paper+Oral+Presentation+at+ESMO+2026+for+Phase+1+Clinical+Study+of+XmAb819+in+Advanced+Clear+Cell+Renal+Cell+Carcinoma/26782454.html Fri, 17 Jul 2026 09:11:00 -0400 A.11505694 O.00017340 O.71890331 XNCR http://www.streetinsider.com/Business+Wire/Xencor+Announces+Proffered+Paper+Oral+Presentation+at+ESMO+2026+for+Phase+1+Clinical+Study+of+XmAb819+in+Advanced+Clear+Cell+Renal+Cell+Carcinoma/26782454.html <p class="bwalignc">-- ESMO presentation to highlight expansion-cohort results for IV doses evaluated for recommended Phase 3 dose --</p><p class="bwalignc">-- Pivotal study of XmAb819 monotherapy in advanced ccRCC, planned to begin in 2027 --</p> <p> PASADENA, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl">Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that results from a Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in advanced clear cell renal cell carcinoma (ccRCC) were accepted for a proffered paper oral presentation at the European Society of Medical Oncology (ESMO) http://www.streetinsider.com/Business+Wire/Xencor+Announces+Proffered+Paper+Oral+Presentation+at+ESMO+2026+for+Phase+1+Clinical+Study+of+XmAb819+in+Advanced+Clear+Cell+Renal+Cell+Carcinoma/26782454.html Fri, 17 Jul 2026 09:11:00 -0400 A.11505694 O.00017340 O.71890331 XNCR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+GORMAN+KEVIN+CHARLES/26748607.html si-local-file:///var/storage/secattach/20260708/26748607.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+GORMAN+KEVIN+CHARLES/26748607.html Wed, 08 Jul 2026 18:55:00 -0400 O.00017340 XNCR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+GORMAN+KEVIN+CHARLES/26748607.html si-local-file:///var/storage/secattach/20260708/26748607.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+GORMAN+KEVIN+CHARLES/26748607.html Wed, 08 Jul 2026 18:55:00 -0400 O.00017340 XNCR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+Feigal+Ellen/26748608.html si-local-file:///var/storage/secattach/20260708/26748608.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+Feigal+Ellen/26748608.html Wed, 08 Jul 2026 18:55:00 -0400 O.00017340 XNCR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+Feigal+Ellen/26748608.html si-local-file:///var/storage/secattach/20260708/26748608.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+Feigal+Ellen/26748608.html Wed, 08 Jul 2026 18:55:00 -0400 O.00017340 XNCR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+Montgomery+Alan+Bruce/26748602.html si-local-file:///var/storage/secattach/20260708/26748602.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+Montgomery+Alan+Bruce/26748602.html Wed, 08 Jul 2026 18:54:00 -0400 O.00017340 XNCR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+Montgomery+Alan+Bruce/26748602.html si-local-file:///var/storage/secattach/20260708/26748602.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+Montgomery+Alan+Bruce/26748602.html Wed, 08 Jul 2026 18:54:00 -0400 O.00017340 XNCR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+Klencke+Barbara/26748604.html si-local-file:///var/storage/secattach/20260708/26748604.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+Klencke+Barbara/26748604.html Wed, 08 Jul 2026 18:54:00 -0400 O.00017340 XNCR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+Klencke+Barbara/26748604.html si-local-file:///var/storage/secattach/20260708/26748604.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+Klencke+Barbara/26748604.html Wed, 08 Jul 2026 18:54:00 -0400 O.00017340 XNCR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+GUSTAFSON+KURT+A/26748605.html si-local-file:///var/storage/secattach/20260708/26748605.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+GUSTAFSON+KURT+A/26748605.html Wed, 08 Jul 2026 18:54:00 -0400 O.00017340 XNCR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+GUSTAFSON+KURT+A/26748605.html si-local-file:///var/storage/secattach/20260708/26748605.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+GUSTAFSON+KURT+A/26748605.html Wed, 08 Jul 2026 18:54:00 -0400 O.00017340 XNCR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+RANIERI+RICHARD+J/26748600.html si-local-file:///var/storage/secattach/20260708/26748600.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+RANIERI+RICHARD+J/26748600.html Wed, 08 Jul 2026 18:53:00 -0400 O.00017340 XNCR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+RANIERI+RICHARD+J/26748600.html si-local-file:///var/storage/secattach/20260708/26748600.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+RANIERI+RICHARD+J/26748600.html Wed, 08 Jul 2026 18:53:00 -0400 O.00017340 XNCR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+Deshaies+Raymond+Joseph/26748597.html si-local-file:///var/storage/secattach/20260708/26748597.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Xencor+Inc++++++++++++++++For%3A+Jun+16++Filed+by%3A+Deshaies+Raymond+Joseph/26748597.html Wed, 08 Jul 2026 18:52:00 -0400 O.00017340 XNCR